Friday, May 27, 2022
High Yields Cannabis/Marijuana/ Weed News
  • Home
  • Cannabis Stocks
  • Cannabis Strains
  • Cannabis Laws
    • Marijuana Laws in All 50 States
    • International Marijuana Laws 2021
  • Product Reviews
  • Growing
  • Write for Us
No Result
View All Result
  • Home
  • Cannabis Stocks
  • Cannabis Strains
  • Cannabis Laws
    • Marijuana Laws in All 50 States
    • International Marijuana Laws 2021
  • Product Reviews
  • Growing
  • Write for Us
No Result
View All Result
High Yields
No Result
View All Result
Home Cannabis Stock Quotes & News

2021 half-year financial and business

Jeremy Vedder by Jeremy Vedder
October 4, 2021
in Cannabis Stock Quotes & News
0
2021 half-year financial and business

NFL Biosciences: 2021 half-year financial and business report

Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2021)

READ ALSO

EnWave Reports 2022 Second Quarter Consolidated Interim

Water Ways Reports Q1 2022 Financial Results Sales of

CESTO II Phase II/III clinical trial approved in Australia (May 2021) and France (September 2021)

Clinical team strengthened

NFL Bioscience’s patent issued in the US (September 2021)

“Innovative company” qualification by BPIfrance recognized

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, is releasing its 2021 half-year financial report and an update on its business following its admission to Euronext Growth Paris at the beginning of July 2021.

Admission to Euronext Growth Paris: €5m raised

NFL Biosciences shares have been listed on Euronext Growth Paris since July 5, 2021, following a €5m capital increase (gross), with the price per share set at €3.80. The transaction was subscribed for by longstanding shareholders, institutional investors and individual investors, all aware of the potential global public health impact of the development of innovative treatments in the dependence and addiction field. These resources will enable NFL Biosciences to accelerate its development by:

  • carrying out the Phase II/III clinical trial for its smoking cessation aid drug candidate NFL-101;
  • recruiting experienced experts to further strengthen its organization;
  • launching the NFL-201 and NFL-301 programs, for the treatment of cannabis addiction and the reduction of alcohol consumption.

During the last few months, NFL Biosciences has moved forward with its operations in line with its business plan and objectives.

Phase II/III clinical trial for NFL-101 approved by the regulatory authorities in Australia in May and France in September

In line with its business plan presented at the time of its capital increase, the Phase II/III clinical trial approved at the end of May 2021 in Australia1, a country well known for the quality of its clinical trials and the availability of competitive research tax credits, has also been approved by the French National Agency for the Safety of Medicines and Health Products (ANSM) and also received a favorable opinion from the French Ethical Review Board (CPP) in September 2021.

The Phase II/III clinical trial – CESTO II – will include 318 smokers, aged 18 and over. The trial will be international, multicentric, randomized, double blind and placebo controlled. It will include three arms (two dose arms and one placebo arm) and patients will be monitores during 12 months. CESTO II’s primary objectives are to select the best dose and assess the efficacy of NFL-101 versus placebo, for both immediate and gradual smoking cessation. The main criteria for assessment are the person’s continued abstinence for four weeks (US Food & Drug Administration (FDA) criterion) and six months (European Medicines Agency (EMA) criterion). The biomarkers used to confirm abstinence are exhaled carbon monoxide and urinary cotinine. A range of secondary criteria will also be assessed, including the number of cigarettes smoked, withdrawal symptoms and level of craving.

The clinical centers where the first patients will be recruited over the coming weeks, are the University of Tasmania (UTAS) clinical centers in Hobart and Launceston in Australia, to be followed by the Clinical Investigation Centers (CIC) at the Poitiers, Bordeaux and Rennes hospitals in France.

Two dedicated additions to lead the CESTO II clinical trial

As envisaged after the capital increase, NFL Biosciences has recruited a Medical Operations Director, who will head up the CESTO II clinical trial and future clinical trials. Dr. Violaine Desort-Henin has more than 12 years’ experience in clinical project implementation for biotechnology companies and pharmaceutical groups. Her expertise has been further strengthened with the recruitment of a Senior Clinical Project Leader, enabling NFL Biosciences to achieve operational capacity to monitor progress with CESTO II. Marie-Laure Fraisse has 15 years’ experience managing international and multicentric clinical projects at various stages of maturity.

NFL Biosciences patent registered in the United States

On September 21, 2021, the United States Patent and Trademark Office (USPTO) issued, with number US 11,123,395, the product patent for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves, focused primarily on smoking cessation. The addition of cannabis proteins to the extract is covered by one of the claims with a view to a potential future use for cannabis cessation. This patent protects the innovation that NFL-101 is based on through to 2036 in the United States. This patent is also issued in France through to 2036. National registration applications are in the review phase in the following regions and countries: China, Japan, Canada, South Korea, Australia, Brazil, India, Indonesia, Israel, Mexico, Philippines, Eurasia, Saudi Arabia, United Arab Emirates, Nigeria.

2021 first-half year financials (January 1 – June 30, 2021)

The accounts for the first half of 2021, prepared in accordance with French GAAP, were approved by the Board of Directors during its meeting on September 30, 2021. The accounts have been subject to a limited review by the statutory auditors. The accounts for the period do not include the results of the capital increase, which had a settlement-delivery date of July 2, 2021.

Corporate accounts (€) June 30, 2021
(6 months)
December 31, 2020
(12 months)
Net revenues – –
Total operating income – –
EBIT (221,051) (318,028)
Financial income (expense) (354) –
Non-recurring income (expense) – 4,984
Net income (221,405) (261,500)
Shareholders’ equity (71,380) 150,025
Intangible assets (patents) 120,566 108,946
Liabilities 1,247,447 174,613
Cash and cash equivalents 175,972 310,201
Balance sheet total 1,428,067 576,638

NFL Biosciences qualified as an “Innovative Company” by BPIfrance

The “Innovative Company” qualification allows a Funds Common Placement in l’Innovation (FCPI) to count its possible participation in NFL Biosciences in the mandatory part of its investment in innovative companies, as defined in I of article L. 214-41 of the Monetary and Financial Code.

Outlook

Dr Ignacio Faus, NFL Biosciences CEO, said: “The need for smoking cessation has increased as a result of the Covid-19 pandemic, while the pharmacological treatments available are unchanged, are relatively ineffective over the long term, are quite difficult to monitor and are sometimes subject to limiting side-effects. NFL Biosciences has set up a clinical team that will work with our CROs, Eurofins Optimed and bow and with the five clinical centers in France and Australia, where the patients, smokers who would like to make a new attempt to stop, will be recruited and treated over the coming quarters. We are also working to assess other countries so that we can be in a position to complete our recruitment as quickly as possible”.

Over the coming months, NFL Biosciences will continue to further strengthen its governance operations.

The assessment of the projects for the treatment of cannabis dependence (NFL-201) and alcohol dependence (NFL-301) will continue to move forward.

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based nearby Montpellier, France, whose most advanced botanical drug candidate is an aid to stop smoking. Known as NFL-101, this natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. NFL Biosciences aims to offer smokers who would like to stop a safe, natural solution that is effective over the long-term, with short-term personalized administration.

Alongside NFL-101, NFL Biosciences has various development projects focused on botanical drugs for the treatment of cannabis use disorder and alcoholism.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contact

NFL Biosciences: Bruno Lafont – info@nflbiosciences.com – +33 4 11 93 76 67

PR Agency: Calyptus – nflbiosciences@calyptus.net – +33 1 53 65 68 68


1 Approved by the Bellberry Human Research Ethics Committee (HREC) and the University of Tasmania (UTAS)

[Original Source]

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0

Related Posts

MedMen’s Tracy McCourt appointed President of West Hollywood cannabis organization
Cannabis Stock Quotes & News

EnWave Reports 2022 Second Quarter Consolidated Interim

May 27, 2022
American Green, Inc.™ (OTC:ERBB) CBD Water with Vessl® Cap
Cannabis Stock Quotes & News

Water Ways Reports Q1 2022 Financial Results Sales of

May 27, 2022
HEXO appoints Chief People & Culture Officer
Cannabis Stock Quotes & News

Resonate Blends partners with California’s top licensed cannabis wholesaling platform, Nabis

May 27, 2022
Fire & Flower and Hifyre announce proposed acquisition of PotGuide
Cannabis Stock Quotes & News

New York’s Office of Cannabis Management ask TikTok to allow educational cannabis PSAs

May 26, 2022
How to throw the cannabis wedding of your dreams
Cannabis Stock Quotes & News

How to throw the cannabis wedding of your dreams

May 26, 2022
Medical Marijuana, Inc. CEO Featured on Seeking Alpha’s CEO
Cannabis Stock Quotes & News

California cannabis companies brace for environmental law compliance

May 26, 2022
Next Post
Availability of the Half Year Financial

Availability of the Half Year Financial

  • Trending
  • Comments
  • Latest
Monthly Spotlight: The Best of Plain Jane CBD

Monthly Spotlight: The Best of Plain Jane CBD

April 8, 2022
The Ultimate Dr. Dabber Stella Vaporizer Review for 2022

The Ultimate Dr. Dabber Stella Vaporizer Review for 2022

April 19, 2022
volcano hybrid review 2022

The 2022 Volcano Hybrid Vaporizer Review: All You Need To Know

May 23, 2022
The Utillian 5 v3 Wax Pen Review for 2022

The Utillian 5 v3 Wax Pen Review for 2022

March 27, 2022

The 7 Best Smell-Proof Weed Bags To Keep Your Bud Stash Safe

April 27, 2022
The Best Synthetic Urine Kit to Pass Your Drug Test in 2022

The Best Synthetic Urine Kit to Pass Your Drug Test in 2022

May 23, 2022
The 10 Best Smell Proof Backpacks for Weed in 2022

The 10 Best Smell Proof Backpacks for Weed in 2022

May 5, 2022
MedMen’s Tracy McCourt appointed President of West Hollywood cannabis organization

EnWave Reports 2022 Second Quarter Consolidated Interim

May 27, 2022
Former NFL Running Back Marshawn Lynch Launches Premium Blunt Brand

Former NFL Running Back Marshawn Lynch Launches Premium Blunt Brand

0
Major Marijuana Coalition Forms To Coordinate Legalization Push, But Some Key Advocacy Players Aren’t Involved

Major Marijuana Coalition Forms To Coordinate Legalization Push

0
MMJRecs - cannabis leaf

How Medical Marijuana Can Help Treat Sleep Disorders

0
Colorado Cannabis Sales Exceed $2 Billion in 2020

Colorado Cannabis Sales Exceed $2 Billion in 2020

0
MedMen’s Tracy McCourt appointed President of West Hollywood cannabis organization

EnWave Reports 2022 Second Quarter Consolidated Interim

May 27, 2022
American Green, Inc.™ (OTC:ERBB) CBD Water with Vessl® Cap

Water Ways Reports Q1 2022 Financial Results Sales of

May 27, 2022
HEXO appoints Chief People & Culture Officer

Resonate Blends partners with California’s top licensed cannabis wholesaling platform, Nabis

May 27, 2022
Fire & Flower and Hifyre announce proposed acquisition of PotGuide

New York’s Office of Cannabis Management ask TikTok to allow educational cannabis PSAs

May 26, 2022

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • March 2020

Categories

  • 1933 Industries
  • 4front Ventures
  • Acreage Holdings
  • Ascend Wellness
  • Ayr Wellness
  • Body & Mind
  • C21 Investments
  • Cannabis Stock Quotes & News
  • Cansortium Inc
  • Captor Capital
  • Ceres Acquisition Corp
  • Chalice Brands
  • Columbia Care
  • Cresco Labs
  • CuraLeaf
  • Gage Growth
  • Glass House Brands
  • Green Thumb Industries
  • Grown Rogue International
  • Harborside
  • Item 9 Labs
  • Jushi Holdings
  • Lowell Farms
  • MariMed
  • MedMen Enterprises
  • News
  • Next Green Wave
  • Planet 13
  • Plus Products
  • Product Reviews
  • Red White & Bloom
  • SLANG Worldwide
  • Sol Global Investments
  • TerrAscend
  • TILT Holdings
  • Trulieve
  • Verano Holdings
  • Vext Sciences
  • Vibe Growth

Recent Posts

  • EnWave Reports 2022 Second Quarter Consolidated Interim
  • Water Ways Reports Q1 2022 Financial Results Sales of
  • Resonate Blends partners with California’s top licensed cannabis wholesaling platform, Nabis
  • New York’s Office of Cannabis Management ask TikTok to allow educational cannabis PSAs

QR Code

2021 half-year financial and business
No Result
View All Result
  • Homepages
    • Home Page 1
  • News

© 2021 High Yields